Zogenix Funding & Investors
Zogenix, Inc. operates as a specialty pharmaceutical company with proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. The Company offers product candidates include a product that enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine.
zogenix.comTotal Amount Raised: $228,962,160
Zogenix Funding Rounds
Post Ipo Debt
$30,000,000
Post Ipo Debt Investors
HealthCare Royalty PartnersPost Ipo Debt
$30,000,000
Post Ipo Debt Investors
HealthCare Royalty PartnersDebt Financing
$35,000,000
Debt Financing Investors
Oxford FinanceSilicon Valley BankSeries Unknown
$15,000,000
Series Unknown Investors
Oxford FinanceDomain AssociatesScale Venture PartnersClarus VenturesChicago Growth PartnersThomas McNerney & PartnersAbingworthSeries B
$35,004,188
Series B Investors
Chicago Growth PartnersSeries B
$35,957,968
Series B Investors
Domain AssociatesClarus VenturesScale Venture PartnersOxford FinanceAbingworthSeries B
$18,000,000
Series B Investors
AbingworthClarus VenturesScale Venture PartnersDomain AssociatesSeries Unknown
$15,000,000
Series Unknown Investors
Oxford FinanceDomain AssociatesScale Venture PartnersClarus VenturesChicago Growth PartnersThomas McNerney & PartnersAbingworthSeries B
$35,004,188
Series B Investors
Chicago Growth PartnersSeries B
$35,957,968
Series B Investors
Domain AssociatesClarus VenturesScale Venture PartnersOxford FinanceAbingworthSeries B
$18,000,000
Series B Investors
AbingworthClarus VenturesScale Venture PartnersDomain AssociatesSeries A
$60,000,000
Series A Investors
Clarus VenturesDomain AssociatesThomas McNerney & PartnersScale Venture PartnersLife Science AngelsSeries A
$60,000,000
Series A Investors
Clarus VenturesDomain AssociatesThomas McNerney & PartnersScale Venture PartnersLife Science Angels
Funding info provided by Diffbot.